I
107TH CONGRESS
1ST SESSION
H. R. 2629
To amend the Public Health Service Act to provide for research, information,
and education with respect to blood cancer.
IN THE HOUSE OF REPRESENTATIVES
Mr. CRANE (for himself, Mrs. ROUKEMA, Mr. SNYDER, Mr. FERGUSON, Mrs.
MCCARTHY of New York, Mr. MCGOVERN, Mrs. MORELLA, Ms. HARMAN,
Mr. GREENWOOD, Mr. SHIMKUS, Mr. HALL of Ohio, Mr. RUSH, and Ms.
SLAUGHTER) introduced the following bill; which was referred to the
Committee on Energy and Commerce
A BILL
To amend the Public Health Service Act to provide for
research, information, and education with respect to
blood cancer.
Be it enacted by the Senate and House of Representa-
tives of the United States of America in Congress assembled,
SECTION 1. SHORT TITLE.
This Act may be cited as the ‘‘Hematological Cancer
Research Investment and Education Act of 2001’’.
SEC. 2. FINDINGS.
Congress finds that:
(1) An estimated 109,500 people in the United
States will be diagnosed with leukemia, lymphoma,
and multiple myeloma in 2001.
(2) New cases of the blood cancers described in
paragraph (1) account for 8.6 percent of new cancer
cases.
(3) Those devastating blood cancers will cause
the deaths of an estimated 60,300 persons in the
United States in 2001. Every 9 minutes, a person
in the United States dies from leukemia, lymphoma,
or multiple myeloma.
(4) While less than 5 percent of Federal funds
for cancer research are spent on those blood cancers,
those blood cancers cause 11 percent of all cancer
deaths in the United States.
(5) Increased Federal support of research into
leukemia, lymphoma, and multiple myeloma has re-
sulted and will continue to result in significant ad-
vances in the treatment, and ultimately the cure, of
those blood cancers as well as other cancers.
SEC. 3. RESEARCH, INFORMATION, AND EDUCATION WITH
RESPECT TO BLOOD CANCER.
Part B of title IV of the Public Health Service Act
(42 U.S.C. 284 et seq.) is amended by adding at the end
the following:
‘‘SEC. 409I. RESEARCH, INFORMATION, AND EDUCATION
WITH RESPECT TO BLOOD CANCER.
‘‘(a) RESEARCH.—
‘‘(1) IN GENERAL.—The Director of NIH shall
expand, intensify, and coordinate programs for the
conduct and support of research with respect to
blood cancer, and particularly with respect to leu-
kemia, lymphoma, and multiple myeloma.
‘‘(2) ADMINISTRATION.—The Director of NIH
shall carry out this subsection through the Director
of the National Cancer Institute and in collaboration
with any other agencies that the Director determines
to be appropriate.
‘‘(3) AUTHORIZATION
OF
APPROPRIATIONS.—
For the purpose of carrying out this subsection,
there is authorized to be appropriated $250,000,000
for fiscal year 2002 and each subsequent fiscal year.
Such authorizations of appropriations are in addi-
tion to other authorizations of appropriations that
are available for such purpose.
‘‘(b) JOE
MOAKLEY
CANCER
EDUCATION
PRO-
GRAM.—
‘‘(1) IN GENERAL.—The Director of the Cen-
ters for Disease Control and Prevention, in collabo-
ration with the Director of NIH, shall establish and
carry out a program to provide information and edu-
cation for patients and the general public with re-
spect to blood cancer, and particularly with respect
to the treatment of leukemia, lymphoma, and mul-
tiple myeloma.
‘‘(2) ADMINISTRATION.—The Director of the
Centers for Disease Control and Prevention shall
carry out this subsection in collaboration with pri-
vate health organizations that have national edu-
cation and patient assistance programs on blood-re-
lated cancers.
‘‘(3) AUTHORIZATION
OF
APPROPRIATIONS.—
For the purpose of carrying out this subsection,
there is authorized to be appropriated $25,000,000
for fiscal year 2002 and each subsequent fiscal year.
Such authorizations of appropriations are in addi-
tion to other authorizations of appropriations that
are available for such purpose.’’.
Æ